Clinical Trials

A clinical trial (or study) is an experiment that involves research using human volunteers and is intended to add to medical knowledge. Clinical trials involving people living with HIV are ongoing and can further our knowledge about the virus and contribute to cure research. Click on the links below to learn more about current clinical trials.

arrow&v
Reprieve logo

Obesity and Healthy Thinking Study

Obesity and Healthy Thinking Study This study is being done to learn if Egrifta may improve brain function in HIV positive people with abdominal obesity, which increases the risk for impaired thinking. Call Rod Hagan at 760.507.3321

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

DAP Health

The mission of DAPHealth is to enhance and promote the health and well-being of our community.

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

GSK “Eagle-2” NCT ID #: NCT04020341


A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)


Sponsor:

GlaxoSmithKline

pdf.png
pdf.png
Reprieve logo

Gilead “Calibrate” NCT ID #: NCT04143594

A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV

Sponsor:

Gilead

pdf.png
pdf.png
Reprieve logo

GSK “Eagle-1” NCT ID #: NCT04010539

A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae

Sponsor:

GlaxoSmithKline

pdf.png
pdf.png
Reprieve logo

Gilead “Capella” NCT ID #: NCT04150068

A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance.


Sponsor:

Gilead

pdf.png
pdf.png
Reprieve logo

REPRIEVE Randomized Trial to Prevent Vascular Events in HIV

People living with HIV are 50–100% more likely to develop heart disease (including heart attack and stroke) than people without HIV. REPRIEVE is a clinical research trial exploring long-term prevention of heart disease among people living with HIV. Call: 1-877-29-HEART Leah Lane 760-834-7949

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

Merck “Illuminate” MK 8591A-018

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in Participants with HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Sponsor:

Merck Sharp & Dohme Corp.

pdf.png
pdf.png
Reprieve logo

Neuropathic Pain & Cannabis Study

Neuropathic Pain & Cannabis Study


  • Effect of cannabis on HIV neuropathic pain

  • 6 month +

  • HIV+ & HIV-related Neuropathic Pain

  • 2 components :

  • Daily text messaging / surveys (6 months)

  • Cannabis administration (3 office visits)

  • Initial screen (1 hour)

  • In-person medical screen (6-8 hours)

  • If eligible, enroll in either or both

  • Compensation up to $570


For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

Tesamorelin Abdominal Fat Study

Tesamorelin Abdominal Fat Study


  • Cognitive improvements from using Tesamorlin

  • 1-year study

  • HIV+ with abdominal fat 40 y/o

  • Spanish or English

  • Multiple In-person screening visits

  • Immediate group or delayed group

  • Daily Text messaging

  • Self-administer medication for 6 months

  • 5 study visits, plus phone visits

  • Compensation up to $635 w/ optional LPs



For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

Nicotine and HIV Study

Nicotine and HIV Study


  • Effects of nicotine on the brain

  • 1 visit – baseline only – (8 hours)

  • Some candidates may qualify: MRI / PET visits separately

  • HIV+/-

  • Current Smokers

  • Initial screen (1 hour)

  • 1 visit - Compensation up to $90

  • Possible MRI and or PET scan addtional compensation up to $177.40


For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

Health in Older Latinos Study

Health in Older Latinos Study


  • Ethnic and racial differences in the cognitive effects of HIV

  • 3visits -3years

  • Latino HIV+/-

  • Spanish or English

  • Initial screen (1 hour)

  • Compensation up to $305


For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

Diet & Physical Activity Study

Diet & Physical Activity Study


  • Assess ways to increase moderate physical activity & improve diet

  • 1-year study

  • HIV+ and able to increase moderate physical activity

  • Initial screen (2 hours)

  • 2 In-person visits (6-8 hours), 1 phone visit at end

  • Daily text messaging (6 months)

  • Fit bit and accelerometer

  • May include Walnuts and Olive Oil

  • Compensation up to $465



For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

Virtual Reality Assessment of How HIV Affects Cognitive and Balance Problems

Virtual Reality Assessment Study


  • VR assessment for Cognitive and Balance

  • 2.5-year study

  • HIV+ 60+y/o

  • Initial screen (1 - 1 1⁄2 hours)

  • 8 visits over 2 years

  • 5 HNRP visits – (full & partial visits)

  • 3 SDSU visits for hearing tests

  • Compensation up to $390



For futher details regarding this study, or other studies please call (619) 543-5000 and ask to speak with a recruiter and view the pdf below.

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

COVID-19 STUDY FOR OUTPATIENTS

DID YOU JUST GET TESTED FOR COVID-19 

but are not sick enough to be hospitalized?


Palmtree Clinical Research, Inc. (PCR, Inc.) is currently enrolling for a COVID-19 clinical trial. We are looking for patients who have recently tested positive for COVID-19.


This is an outpatient trial, 5 visits (3 in-clinic and 2 phone calls) over about a month period, with the Investigational Product being Camostat (PO, QID x 14 days).


You May Qualify If You


  • Just received a POSITIVE COVID-19 test result or less than 3days ago 

  • Are at least18 years old

  • Do not need to be treated in the hospital right now

  • Can come to the clinic to sign-up and complete 2 more visits


Have just one risk factor below along with a positive COVID-19 test: 


  • Are age 65 or older

  • Have diabetes mellitus (Type 1 or Type 2)

  • Have high blood pressure

  • Have chronic heart, lung, or liver disease, or 

  • Are 35 lbs or more overweight


Participation Involves


  • Taking tablets for 14 days of treatment

  • Keeping a daily log of your temperature once a day

  • Three (3) short clinic visits for nasal swabs and blood draws


PARTICIPANTS WILL BE COMPENSATED FOR THEIR PARTICIPATION


CALL OR EMAIL FOR MORE INFORMATION ABOUT THE CAMELOT TRIAL Please call: 760-778-7799 Email: contact@palmtreeclinical.com


555 E Tachevah Drive, Suite 1E-201, Palm Springs, CA 92262

(Located across from Desert Regional Hospital in the Las Palmas Medical Plaza)

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

Illuminate HTE Clinical Trial

Illuminate HTE Study


Illuminate HTE Study a Phase 3 clinical trial evaluating an oral, once-daily investigational medication, a fixed-dose combination of doravirine/islatravir (DOR/ISL), in participants with HIV-1 who are heavily treatment experienced and failing on their current antiretroviral therapy (ART).

Sponsor:

Merck

pdf.png
pdf.png
Reprieve logo

Investigational HIV Treatment

Recruiting participants who have a current viral load >400 copies : Investigating PRO 140 subcutaneous injection once weekly combine with OBT in treatment experienced patients.

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

idiopathic pulmonary fibrosis (IPF)

The GALACTIC-1 study will research a potential study drug that could offer benefit to patients with IPF. Thank you for considering participation in this trial.

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

Search Current Clinical Trials

Clinicians at Eisenhower Medical Center continue to take part in groundbreaking research, including: interventional cardiology, orthopedics, novel biotherapies in oncology, targeted therapies base on molecular profile of cancer, early detection of cancer via specialized imaging, drugs aimed at improving survival of HIV patients, and use of integrative therapies to reduce side effects related to cancer treatment.

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

Search Government Clinical Trials

Explore 311,636 research studies in all 50 states and in 209 countries. ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine.

Sponsor:

none

pdf.png
pdf.png
Reprieve logo

Live Healthy Study: Smoking Cessation

UCSD Live Healthy Study


Who can participate?

Persons living with HIV who smoke or recently quit smoking


What does participation involve?

Questionnaire (35-45 minutes).  Compensation is $30.

AND/OR

Focus Group (1-1.5 hours). Compensation is $35.How to participate?


All participation is remotePlease click this link to complete the eligibility screener:https://tinyurl.com/yyvhuahe

(If the link does not work, please copy and paste it into your web browser)


If you are eligible, you will be invited to complete the main survey.  Focus groups are conducted remotely via Zoom or phone.

Sponsor:

none

pdf.png
pdf.png